Immune System Diseases Completed Phase 3 Trials for Dupilumab (DB12159)

Also known as: Immune System Disease

IndicationStatusPhase
DBCOND0029769 (Immune System Diseases)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03720470Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical TherapyTreatment